SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
Rhea-AI Summary
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings extensive experience in biochemistry, molecular biology, and cellular biology. He has a proven track record in developing new methods for cell model creation, protein expression, and DNA/RNA production. Notably, Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology.
Dr. Kawamura's appointment is expected to enhance SOHM's scientific capabilities and support the advancement and commercialization of their ABBIE gene editing technology. The company anticipates that his expertise will aid in the timely release of ABBIE kits, as previously announced for the current quarter.
Positive
- Appointment of Dr. Tetsuya Kawamura, a highly qualified expert in biochemistry and cellular biology
- Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology
- Expected to enhance SOHM's scientific capabilities and support ABBIE gene editing technology commercialization
- Anticipated to aid in the timely release of ABBIE kits in the current quarter
Negative
- None.
CHINO HILLS, CA / ACCESSWIRE / August 2, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced today the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Cell Engineer and Biochemist.
Baron Night, CEO shared that, we are excited to announce the addition of Dr. Tetsuya Kawamura, Ph.D., to our team as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings a wealth of experience and expertise in the fields of biochemistry, molecular biology, and cellular biology, further enhancing SOHM's commitment to scientific excellence and innovation.
Dr. Kawamura is a distinguished life science professional with extensive experience in biochemistry, molecular, and cellular biology. He has a proven track record of developing new methods and utilizing various instruments for analytical characterization relevant to cell model creation, protein expression and purification, and DNA/RNA production. His productivity, problem-solving skills, and broad knowledge base make him a valuable asset to SOHM. Moreover, Dr. Kawamura has authored patents in gene editing technology, including our own ABBIE technology. Dr. Kawamura has an extensive peer reviewed publication track record and will also support grant writing initiatives. Mr. Night added.
Dr. Kawamura holds a Ph.D. in Chemistry from the University of California, Santa Barbara, an M.S. in Chemistry from the University of Oregon, Eugene, and a B.S. in Music and Biochemistry from California Polytechnic State University, San Luis Obispo.
Dr. Kawamura's diverse academic background and professional experience with genome editing, molecular biology, and biochemistry will be instrumental in our advancement and commercialization of ABBIE gene editing technology. His entry greatly aids our timely release of ABBIE kits as we announced earlier in the current quarter.
For more information about SOHM Inc. and its work on ABBIE, please visit www.SOHM.com
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
Who is Dr. Tetsuya Kawamura and what role has he taken at SOHM, Inc. (SHMN)?
What is Dr. Kawamura's contribution to SOHM's (SHMN) gene editing technology?
How will Dr. Kawamura's appointment impact SOHM's (SHMN) product development?
What is SOHM, Inc. (SHMN) and what does it specialize in?
